ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Eli Lilly and Company and Sosei Group have inked an agreement to discover drug candidates for diabetes and metabolic diseases. Sosei will use structure-based drug design to find small molecules that selectively go after Lilly-nominated targets on G-protein-coupled receptors (GPCRs). Under the agreement, Sosei will receive $37 million in cash and potentially over $694 million in milestones and royalties.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter